Medindia

X

Amarin Corporation Announces First Patients Enrolled In Two Phase 3 Clinical Trials Assessing AMR101 for the Treatment of Cardiovascular Disease

Tuesday, January 12, 2010 General News J E 4
Advertisement
-Lowering Triglyceride Levels For At-Risk Patients-

Investor Contact Information:

John F. Thero

Chief Financial Officer

In US: +1 (860) 572 4979

investor.relations@amarincorp.com

Gitanjali Ogawa

The Trout Group

In U.S. +1 (646) 378-2949

gogawa@troutgroup.com

International Media Contact Information:

Mark Swallow or David Dible

Citigate Dewe Rogerson

In UK: +44 (0)207 638 9571

mark.swallow@citigatedr.co.uk

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
VIVUS Announces Additional Results of Phase 3 avan...
S
Idenix Pharmaceuticals Highlights Progress in Thre...